No label defined (Q3138701)

From EU Knowledge Graph
Revision as of 13:19, 12 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): OBJECTIVE: To examine if the prophylactic use of vaginal Utrogestan from the first-trimester of pregnancy in women with twin pregnancy can reduce the incidence of spontaneous delivery before 34 weeks. METHODS: Phase III two-arm double-blinded randomised controlled trial to examine the effect of prophylactic pravastatin from 35-37 weeks’ gestation in women at increased risk for term-PE on the incidence and severity of the disease PRIMARY OUTCOME...)
Jump to navigation Jump to search
Project Q3138701 in Spain
Language Label Description Also known as
English
No label defined
Project Q3138701 in Spain

    Statements

    contained in NUTS
    Murcia
    0 references
    country
    Spain
    0 references
    EU contribution
    81,600.0 Euro
    0 references
    budget
    102,000.0 Euro
    0 references
    co-financing rate
    80.0 percent
    0 references
    start time
    1 January 2018
    0 references
    end time
    31 March 2021
    0 references
    beneficiary name (string)
    FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
    0 references
    beneficiary
    Q3136857
    0 references
    coordinate location

    37°59'32.57"N, 1°7'49.94"W
    0 references
    postal code
    30030
    0 references
    summary
    OBJECTIVE: To examine if the prophylactic use of vaginal Utrogestan from the first-trimester of pregnancy in women with twin pregnancy can reduce the incidence of spontaneous delivery before 34 weeks. METHODS: Phase III two-arm double-blinded randomised controlled trial to examine the effect of prophylactic pravastatin from 35-37 weeks' gestation in women at increased risk for term-PE on the incidence and severity of the disease  PRIMARY OUTCOME: delivery with preeclampsia  SECUNDARY OUTCOME: determine the effect of pravastatin  On adverse outcome of pregnancy at any gestation and at = 37 week´s gestationOn the incidence of stillbirth or neonatal death. On neonatal morbidity  On neonatal therapy  On the incidence of low birth weight below the 3rd, 5th and 10th centile  On sFLT and PLGF value 1 and 3 weeks after the onset of treatment  Pravastatin safety assessment during pregnancy (Spanish)
    0 references
    OBJECTIVE: To examine if the prophylactic use of vaginal Utrogestan from the first-trimester of pregnancy in women with twin pregnancy can reduce the incidence of spontaneous delivery before 34 weeks. METHODS: Phase III two-arm double-blinded randomised controlled trial to examine the effect of prophylactic pravastatin from 35-37 weeks’ gestation in women at increased risk for term-PE on the incidence and severity of the disease PRIMARY OUTCOME: delivery with preeclampsia Secundary OUTCOME: determine the effect of pravastatin On adverse outcome of pregnancy at any gestation and at = 37 week’s gestationOn the incidence of Stillbirth or neonatal death. On neonatal morbidity On neonatal therapy On the incidence of low birth weight below the 3 rd, 5th and 10th centile On sFlt and PlGF value 1 and 3 weeks after the onset of treatment Pravastatin safety assessment during pregnancy (English)
    point in time
    12 October 2021
    0 references
    location (string)
    Murcia
    0 references

    Identifiers

    Spanish Kohesio ID
    PI17_01350
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3138701&oldid=12782254"